Literature DB >> 15877678

Pathogenesis of lupus nephritis: an update.

Sydney Tang1, Sing Leung Lui, Kar Neng Lai.   

Abstract

Lupus nephritis (LN) is a prototypic autoimmune disease. Its immunopathogenesis is characterized by the loss of self-tolerance. In this article, we review our current understanding of the disease mediators of LN. There is ample evidence to suggest a pathogenic role of nephritogenic autoantibodies. These antibodies cross react with nucleosomal epitopes, and the in vivo generation of nucleosomes requires apoptosis. Furthermore, there is an intriguing and paradoxical relationship between complement and systemic lupus erythematosus (SLE). Immune complex-mediated activation of complement through the classic pathway is traditionally believed to be a major mechanism by which tissue injury occurs. In contrast, hereditary deficiencies of complement components increase the risk of SLE. Finally, the roles of reactive nitrogen and oxygen species are emphasized.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15877678     DOI: 10.1111/j.1440-1797.2005.00392.x

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  12 in total

1.  Plasma ficolin levels and risk of nephritis in Danish patients with systemic lupus erythematosus.

Authors:  Nima Tanha; Katrine Pilely; Mikkel Faurschou; Peter Garred; Søren Jacobsen
Journal:  Clin Rheumatol       Date:  2016-12-15       Impact factor: 2.980

2.  Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-Sjögren's syndrome A antibodies.

Authors:  L Mathsson; E Ahlin; C Sjöwall; T Skogh; J Rönnelid
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

3.  Novel biomarkers for the assessment of paediatric systemic lupus erythematosus nephritis.

Authors:  A Koutsonikoli; M Trachana; E Farmaki; V Tzimouli; P Pratsidou-Gertsi; N Printza; A Garyphallos; V Galanopoulou; F Kanakoudi-Tsakalidou; F Papachristou
Journal:  Clin Exp Immunol       Date:  2017-01-22       Impact factor: 4.330

Review 4.  Age-related macular degeneration--emerging pathogenetic and therapeutic concepts.

Authors:  Karen M Gehrs; Don H Anderson; Lincoln V Johnson; Gregory S Hageman
Journal:  Ann Med       Date:  2006       Impact factor: 4.709

5.  The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus.

Authors:  Wenpu Zhao; Seth G Thacker; Jeffrey B Hodgin; Hongyu Zhang; Jeffrey H Wang; James L Park; Ann Randolph; Emily C Somers; Subramaniam Pennathur; Matthias Kretzler; Frank C Brosius; Mariana J Kaplan
Journal:  J Immunol       Date:  2009-07-20       Impact factor: 5.422

6.  Pathogenesis and significance of glomerular C4d deposition in lupus nephritis: activation of classical and lectin pathways.

Authors:  Min-Kyung Kim; Young-In Maeng; Sun-Jae Lee; In Hee Lee; Jisuk Bae; Yu-Na Kang; Byung-Tae Park; Kwan-Kyu Park
Journal:  Int J Clin Exp Pathol       Date:  2013-09-15

7.  Urinary Neutrophil Gelatinase-Associated Lipocalin to Monitor Lupus Nephritis Disease Activity.

Authors:  Hani Susianti; Jullyanny W Wijaya; Ati Rastini; Kusworini Handono; Atma Gunawan; Handono Kalim
Journal:  Biomark Insights       Date:  2015-09-06

8.  The Spectrum of C4d Deposition in Renal Biopsies of Lupus Nephritis Patients.

Authors:  Ying Ding; Xiaojuan Yu; Lihua Wu; Ying Tan; Zhen Qu; Feng Yu
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

9.  The spectrum of renal thrombotic microangiopathy in lupus nephritis.

Authors:  Di Song; Li-hua Wu; Feng-mei Wang; Xiao-wei Yang; Di Zhu; Min Chen; Feng Yu; Gang Liu; Ming-hui Zhao
Journal:  Arthritis Res Ther       Date:  2013-01-15       Impact factor: 5.156

10.  The role of aldosterone blockade in murine lupus nephritis.

Authors:  Seetha U Monrad; Paul D Killen; Marc R Anderson; Amanda Bradke; Mariana J Kaplan
Journal:  Arthritis Res Ther       Date:  2008-01-15       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.